GEP20197052B - Hyr1-derived compositions and methods of treatment using same - Google Patents

Hyr1-derived compositions and methods of treatment using same

Info

Publication number
GEP20197052B
GEP20197052B GEAP201213226A GEAP2012013226A GEP20197052B GE P20197052 B GEP20197052 B GE P20197052B GE AP201213226 A GEAP201213226 A GE AP201213226A GE AP2012013226 A GEAP2012013226 A GE AP2012013226A GE P20197052 B GEP20197052 B GE P20197052B
Authority
GE
Georgia
Prior art keywords
treatment
hyr1
methods
same
derived compositions
Prior art date
Application number
GEAP201213226A
Other languages
English (en)
Inventor
Angeles Biomedical Research Center Los
Original Assignee
Angeles Biomedical Research Center Los
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeles Biomedical Research Center Los filed Critical Angeles Biomedical Research Center Los
Publication of GEP20197052B publication Critical patent/GEP20197052B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GEAP201213226A 2011-09-14 2012-09-14 Hyr1-derived compositions and methods of treatment using same GEP20197052B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161534734P 2011-09-14 2011-09-14
US201161564201P 2011-11-28 2011-11-28

Publications (1)

Publication Number Publication Date
GEP20197052B true GEP20197052B (en) 2019-12-25

Family

ID=47884005

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP201213226A GEP20197052B (en) 2011-09-14 2012-09-14 Hyr1-derived compositions and methods of treatment using same
GEAP201913226A GEAP201913226A (en) 2011-09-14 2012-09-14 Hyr1-derived compositions and methods of treatment using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP201913226A GEAP201913226A (en) 2011-09-14 2012-09-14 Hyr1-derived compositions and methods of treatment using same

Country Status (11)

Country Link
US (1) US10160790B2 (https=)
EP (1) EP2755668A4 (https=)
JP (1) JP2014527084A (https=)
CN (1) CN103998049A (https=)
AU (1) AU2012308281A1 (https=)
BR (1) BR112014005773A2 (https=)
CA (1) CA2848403A1 (https=)
EA (1) EA025831B1 (https=)
GE (2) GEP20197052B (https=)
UA (1) UA115305C2 (https=)
WO (1) WO2013040478A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
US10130691B2 (en) 2013-03-15 2018-11-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for treating fungal and bacterial pathogens
EP2942389A1 (en) * 2014-05-05 2015-11-11 Servicio Andaluz De Salud Vaccine against Acinetobacter baumannii based on lipopolysaccharide-deficient cellular components
GB201503812D0 (en) * 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
CN108472372B (zh) * 2015-07-13 2022-05-17 海港医学中心洛杉矶生物医学研究所 结合不动杆菌的抗体结合剂及其用途
EP3426287A4 (en) 2016-03-09 2020-03-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
GB201902769D0 (en) * 2019-03-01 2019-04-17 Univ Court Of The Univ Of Aberdeen Antibody molcules and uses thereof
US20220354935A1 (en) * 2021-04-21 2022-11-10 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Vaccination against fungal epitopes to prevent inflammatory bowel diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100150942A1 (en) * 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
WO2011003085A1 (en) 2009-07-03 2011-01-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Hyr1 as a target for active and passive immunization against candida

Also Published As

Publication number Publication date
GEAP201913226A (en) 2019-07-10
UA115305C2 (uk) 2017-10-25
EP2755668A4 (en) 2015-07-01
CN103998049A (zh) 2014-08-20
BR112014005773A2 (pt) 2019-09-24
WO2013040478A2 (en) 2013-03-21
US20150191514A1 (en) 2015-07-09
WO2013040478A3 (en) 2013-06-27
AU2012308281A1 (en) 2014-04-24
EA201391199A1 (ru) 2014-04-30
US10160790B2 (en) 2018-12-25
JP2014527084A (ja) 2014-10-09
CA2848403A1 (en) 2013-03-21
EA025831B1 (ru) 2017-02-28
EP2755668A2 (en) 2014-07-23

Similar Documents

Publication Publication Date Title
GEAP201913226A (en) Hyr1-derived compositions and methods of treatment using same
PH12014500904B1 (en) Antibody formulations and methods
MX2022000026A (es) Anticuerpos para tau.
EA202193044A2 (ru) Способы лечения таупатии
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
EA201391553A1 (ru) Композиция и способ усиления иммунного ответа
TN2013000378A1 (en) Anti - sclerostin antibody crystals and formulations thereof
UA113956C2 (xx) Похідні піримідину для лікування вірусних інфекцій
SG178991A1 (en) Anti-gitr antibodies
MY187874A (en) Antibody formulations
MY158992A (en) Forms of rifaximin and uses thereof
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MX359769B (es) Metodos para descelularizar huesos.
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
WO2012173846A3 (en) Peptidomimetic macrocycles
PH12013500616A1 (en) Antibody compositions and methods of use
GB2497453A (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
IN2014DN09450A (https=)
PH12012501548A1 (en) Compositions comprising sugar-cysteine products
ZA201308256B (en) Uses, methods and biological compositions of the genus paecilomyces for the control, prevention and eradication of phytoparasites in solanaceae cultures
MX2013011919A (es) Variantes de factor neurotrófico derivado de celulas gliales humanas.
WO2012166659A3 (en) Anti-emr1 antibodies
GB201114923D0 (en) Immunogenic proteins and compositions